An observational study in HCV, sponsored by Cepheid. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.
Sponsored by Cepheid · Observational
A multi-site prospective, all comers study that was conducted at geographically diverse locations in the United States.
Whole blood specimens were collected from consented individuals with signs and symptoms and/or individuals at-risk of HCV infection, irrespective of HCV antibody status at a single timepoint.
Cepheid is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Specimens collected from individuals showing signs and symptoms and/or at risk of HCV infection
Exclusion Criteria:
Capillary whole blood from individuals with signs and symptoms and/or at-risk of HCV infection
Diagnostic Test: Xpert HCV
Detection of HCV RNA by Xpert HCV test
Percent Agreement compared to Patient infected status (PIS)
Clinical performance comparing Xpert test to PIS (NAAT + Antibody status)
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cepheid